

Hetairos is a histology-based artificial intelligence model for predicting central nervous system tumor methylation subtypes

Received: 26 July 2025

Accepted: 8 May 2026

Published online: 10 June 2026

 Check for updates

A list of authors and their affiliations appears at the end of the paper

Molecular testing is essential for classifying central nervous system (CNS) tumors, with methylation profiling providing the highest diagnostic granularity. However, this requires more resources and time than conventional hematoxylin and eosin (H&E) histopathology, which is widely available globally. Here we propose Hetairos, an artificial intelligence algorithm that predicts 102 methylation-based CNS tumor subtypes from digital H&E slides. Built and validated on 9,606 patients and over 11,000 slides from 11 centers across four continents, Hetairos identified 50–70% of cases with high confidence, achieving an accuracy of 0.87 for its highest-rated predictions. Hetairos outperformed five board-certified neuropathologists in a direct histology-only comparison (0.68 versus 0.30). Prospective evaluation in routine diagnostics confirmed its performance, reducing turnaround time from 12 days (molecular testing) to 12 min. Hetairos supports diagnostic decision-making across the full spectrum of pediatric and adult CNS tumors by narrowing differential diagnoses and guiding efficient testing.

Central nervous system (CNS) tumors encompass a wide range of neoplasms characterized by morphological and molecular heterogeneity. The diagnosis of these tumors has been profoundly changed by various molecular tests, in particular DNA methylation profiling, which has helped establish a granular molecular taxonomy¹. Methylation-based tumor subtyping has been shown to stratify outcomes more accurately than previously established classification systems, leading to its widespread adoption^{2–6}. As a result, the 2021 World Health Organization (WHO) classification of CNS tumors, which distinguishes 108 tumor subtypes, has now incorporated class definitions derived from methylation profiling⁷. For most tumor types and subtypes, methylation profiling is recommended as a desirable diagnostic test and is indispensable for achieving certain diagnoses—such as high-grade astrocytoma with piloid features (HGAP) and diffuse glioneuronal tumors with oligodendroglioma-like features and nuclear clusters (DGONC)—as well as for the molecular subtyping of medulloblastomas or ependymomas.

Despite the successes of methylation-based classification, there are drawbacks to this approach. Firstly, it requires a considerable investment in equipment, making it inaccessible to a substantial portion of

the global population⁸. Furthermore, methylation analysis requires large amounts of tumor material, which can be limiting in the case of stereotactic biopsies⁹. Finally, DNA methylation analysis has a typical turnaround time of 2 weeks, which can delay a definitive diagnosis¹⁰. Faster and more widely accessible methods are therefore needed. While nanopore sequencing shows great potential, it also requires bespoke instruments and fresh or fresh-frozen tissues^{11–13}. Currently, routine diagnosis is still largely based on histopathological assessment of hematoxylin and eosin (H&E)-stained tissue sections—typically the first step in tissue-based diagnostics before molecular testing¹⁴. While histopathological analysis is not sufficient to definitively diagnose the full spectrum of CNS tumors, H&E tissue sections are widely and readily available.

Recent advances in computer vision have led to notable successes in digital pathology. Algorithms have been shown to detect morphological features of molecular alterations and to classify tumors into molecularly defined categories^{15–20}. A series of recent foundation models, trained on hundreds of thousands of histopathology slides to recognize diverse histopathological features, provide the basis for many current digital

✉ e-mail: felix.sahm@med.uni-heidelberg.de; moritz.gerstung@dkfz.de




Fig. 1 | Overview of study cohorts and Hetairos's architecture. **a**, Summary of the internal dataset and the ten external datasets used in this study. Hetairos was trained and evaluated using the UKHD dataset ($n = 6,115$ slides). The trained model was additionally evaluated on a multicenter cohort to ensure generalizability ($n = 5,498$ slides). **b**, Tumor subtype distribution for the UKHD dataset ($n = 6,115$ slides). The outer ring displays the 102 tumor subtypes, while the inner ring denotes their corresponding supertypes. Full names and

abbreviations of tumors are listed in Supplementary Table 1. **c**, Schematic of slide processing by Hetairos. Whole-slide images are split into nonoverlapping tiles, from which features are extracted using a pretrained vision transformer. Tile features, along with age and tumor location, are combined into a slide-level representation. Finally, an MLP predicts probabilities for each of the 102 tumor subtypes from the slide-level representation. dims, dimensions.

pathology models^{21–24}. These advances may be particularly beneficial for diagnosing CNS tumors, which are difficult to identify using conventional histopathological approaches. A recent analysis showed that methylation signals could be estimated from standard diagnostic H&E sections of formalin-fixed, paraffin-embedded (FFPE) tissue, providing a means to diagnose ten different tumor types²⁵. Other studies have demonstrated the possibility of predicting specific molecular alterations^{26,27} and classifying distinct subtypes within diffuse gliomas²⁸ and spinal cord ependymomas²⁹. However, an artificial intelligence (AI)-based diagnostic solution for H&E slides that covers the entire spectrum of CNS tumors, as currently only possible with methylation testing, is still missing.


Here, we describe Hetairos, an AI-based model that classifies whole-slide images of H&E-stained FFPE tissue sections into 102 subtypes of CNS tumors. Hetairos was trained and evaluated on 9,606

tumors, comprising more than 11,000 slides from 11 different institutions across four continents. Hetairos provided high-confidence predictions on 50–70% of the slides, with an accuracy of 0.87. The algorithm outperformed human neuropathologists in a side-by-side assessment of 210 cases selected from the full spectrum of CNS tumors. Lastly, we prospectively evaluated Hetairos in a routine diagnostic setting involving 210 tumor samples. Our results suggest that AI-based predictions can lead to faster diagnoses and help resolve cases with ambiguous results in methylation analysis or insufficient genomic material.

Results

Hetairos is trained to predict 102 tumor subtypes

Hetairos was built using 6,115 slides from 4,961 patients with CNS tumors at the Department of Neuropathology, University Hospital



three most probable (top-3) subtypes predicted by Hetairos. **c**, Scatter plot illustrating the calibration of Hetairos's predicted probabilities. **d**, Hetairos's predictive performance across different confidence intervals. **e**, Scatter plot showing the correlation between training sample size and Hetairos's predicted confidence.

The Hetairos model predicted each of the 102 CNS tumor subtypes from H&E whole-slide scans (Fig. 1c). Because the scanned slides were

The visible clustering of subtypes also reflects Hetairos's ability to distinguish different tumor classes. Hetairos assigns a probability to each possible class, which usually centers around a single class or a few related classes. Of greatest interest is typically the class with the highest




Fig. 3 | Confusion matrix for internal validation by Hetairios ($n = 1,102$ slides). The matrix provides a comprehensive view of classification accuracy across 72 CNS tumor subtypes (classes with a sample size >1), with the vertical axis representing the true classes and the horizontal axis representing the predicted

classes. Each cell displays the percentage of cases in each actual class that are classified into each predicted class. Rectangle boxes group classes that belong to the same superfamily. The sample size of each class is listed on the right.

probability, which we term the top-1 prediction, and the corresponding estimated probability, which we refer to as Hetairios's confidence. Top-1 predictions agreed with the methylation classification results (methylation score > 0.8) in 75% of all internal validation tumors (Fig. 2b) and remained robust in the presence of common histological artifacts (Supplementary Tables 3 and 4); additional performance metrics are provided in Supplementary Table 5. In 87% of cases, the true class label was among Hetairios's three most likely classes (top-3 accuracy). Reassuringly, incorrect predictions were typically assigned lower confidence scores, showing a conservative tendency that is important to avoid confident mispredictions (Fig. 2c). In line with the methylation classifier,

it is important for users of Hetairios to know the confidence levels at which the predictions are typically correct. We designated cases with confidence above 0.5 as 'high confidence' and those with confidence below 0.5 as 'low confidence'. High- and low-confidence cases comprised 70% and 30% of tumors in the internal validation cohort, respectively (Fig. 2d). Hetairios's top-1 accuracy among the high-confidence set was 0.88, demonstrating that the model can deliver an accurate and detailed initial diagnosis in the majority of cases, with accuracy further increasing as the confidence threshold rises (Supplementary Table 6).

In the low-confidence set, the accuracy dropped, as expected, to 0.46. When combining the three most likely predictions for the




Fig. 4 | Performance of Hetairos in external validation ($n = 1,796$ slides). **a**, External validation data consist of nine cohorts from seven countries across four continents. **b**, Bar plots showing the tumor subtype distribution in the external validation set. The observed frequencies closely mirror those of the internal validation set. **c**, Prediction accuracy on the external validation set. Hetairos achieved a top-1 accuracy of 0.68 and a top-3 accuracy of 0.84 in external validation. The green bar denotes the correct predictions, and the pink bar denotes the incorrect ones. **d**, Hetairos's predictive performance across different confidence intervals in external validation. **e**, Scatter plot illustrating the correlation between differences in confidence and differences in accuracy

between internal and external validation. Here, the differences were calculated as the values from the external validation set minus those from the internal validation set. **f,g**, Scatter plots illustrating the correlation between average predicted confidence and accuracy across different cohorts, grouped into high-confidence predictions (**f**) and low-confidence predictions (**g**). UCL, University College London; GHU Paris, Groupe Hospitalier Universitaire Paris Psychiatrie & Neurosciences; JLU Giessen, Justus Liebig University Giessen; UCT Frankfurt, University Cancer Center Frankfurt; ACCCC, AC Camargo Cancer Center; CQMU, Chongqing Medical University; Chile, Pontificia Universidad Católica de Chile.

low-confidence set, the accuracy was still 0.71, which shows that Hetairos can often meaningfully reduce the set of possible diagnoses from 102 subtypes to just 3 even in low-confidence cases. Such narrowing of probable classes may help guide further diagnostic tests, potentially resolving the differential diagnoses with only a few or even a single immunohistochemistry test, single gene assay or chromosomal hybridization, rather than through high-throughput testing.

For half of the errors Hetairos made on the high-confidence cases, the correct class belonged to the same superfamily as the predicted class, resulting in an accuracy of 0.94 at the superfamily level. This pattern reflects the close morphological similarity of these entities and their consistent confusion, even within the hierarchical classification systems (Extended Data Fig. 1a–f). Among the low-confidence set, errors tended to occur across superfamilies and subtypes. In such errors, classes with higher incidence in the training data were predicted more often and with greater confidence. All 12 tumor subtypes with an average confidence below 0.25 had fewer than 20 occurrences in the training set (Figs. 2d,e and 3). Data augmentation strategies, including oversampling and color

space transformation, appeared insufficient to further improve performance on these underrepresented classes (Extended Data Fig. 2a–h). These findings highlight the need for large datasets to confidently classify very rare tumor subtypes, such as liponeurocytomas, atypical teratoid/rhabdoid tumors and germinomas.

Hetairos's accuracy is preserved in external validation cohorts

To be widely applicable, digital pathology models must maintain predictive performance across centers, demographics and processing protocols^{32,33}. To evaluate Hetairos's performance in settings unobserved during training, we assembled ten validation cohorts from different institutions across four continents, comprising 4,645 cases and 5,498 slides covering the incident spectrum of CNS tumor diagnoses (Fig. 4a,b).

Hetairos's overall accuracy was lower in external validation cohorts than in the internal validation cohort (68% versus 75%) (Fig. 4c, Extended Data Fig. 3 and Supplementary Table 5). Reassuringly, however, this discrepancy was largely predicted, as the fraction of low-confidence predictions increased from 30% to 45% (Fig. 4d). This




Fig. 5 | Hetairos outperforms neuropathologists in comparative testing ($n = 210$ slides). **a**, Bar plot comparing the top-1 and top-3 accuracies achieved by Hetairos and five neuropathologists (H1–H5) in the side-by-side comparison. Purple bars represent top-1 accuracy, while green bars represent top-3 accuracy. **b**, Scatter plot comparing the prediction accuracy of Hetairos and neuropathologists across different confidence intervals. Blue dots represent Hetairos's accuracy, while purple dots represent the average accuracy of neuropathologists. The intervals were defined by Hetairos's confidence. **c**, Scatter plot illustrating the correlation between training sample size and the accuracy difference between Hetairos and neuropathologists across tumor subtypes (represented by differently colored dots).

discrepancy may in part be attributed to modality differences between the external and internal validation sets (Extended Data Fig. 4a,b and Supplementary Table 7). Among the 55% high-confidence cases, the top-1 accuracy remained 0.87 (0.96 at the superfamily level), similar to the performance achieved in the internal validation cohort. Among low-confidence cases, the prediction accuracies were 0.45 for top-1 and 0.71 for combined top-3 predictions, consistent with those of low-confidence samples in the internal validation cohort. This provides evidence that Hetairos recognizes differences in slide characteristics and adjusts its confidence levels accordingly.

The change in average confidence per tumor class was -0.10 (range -0.53 to $+0.30$) and was usually accompanied by a corresponding change in observed accuracy, thereby maintaining calibration (Fig. 4e). While 59 of 79 tumor types exhibited a drop in confidence, there was also an increase in confidence and accuracy for 8 of the 79 tumor types, including medulloblastoma group 3 and schwannoma.

The external cohorts have distinct tumor class compositions due to the specialization of the individual centers. Nonetheless, the drop in confidence was of a similar magnitude across subcohorts. The accuracy on the respective high- and low-confidence cases matched or exceeded the model's confidence, indicating that Hetairos's predictions remain conservative (Fig. 4f,g).

Lastly, Hetairos was evaluated qualitatively on the EBRAINS Digital Brain Tumour Atlas (DBTA) cohort, which comprises 3,110 slides lacking methylation-based predictions. Instead, Hetairos predictions were compared to the detailed histopathological diagnoses provided (Extended Data Fig. 5a,b). Specific histology class names and their corresponding color codes are detailed in Supplementary Table 8. In this cohort, Hetairos's confidence distribution was similar to that in other external validation cohorts, showing a 50–50% split between high- and low-confidence cases, with corresponding accuracies of 85.6% and 50.2%, respectively. The predicted tumor types showed good agreement with histopathological diagnoses, with discrepancies mostly occurring within tumor families. Additional results on external samples with low methylation scores (<0.8 , with an average of 0.45) are provided in Extended Data Fig. 5c,d (note that methylation class annotations may differ from the final diagnoses for these cases).

Hetairos outperforms neuropathologists in H&E assessment

Identifying and narrowing differential diagnoses from H&E slides is an important first step in the diagnostic workflow and is pivotal for the efficient selection of subsequent diagnostic tests. While many institutes in high-income countries typically have a set of special stains (for example, PAS and reticulin) and immunohistochemistry tests (for example, GFAP, MAP2, NeuN and synaptophysin) readily available at initial inspection to assess tumor lineage, such diagnostic tools are often absent or restricted to a few cases in settings with more limited resources. Hence, we conducted a blinded side-by-side evaluation of 210 slides by five board-certified neuropathologists and Hetairos. The slides were selected to have a similar number of cases from each class (Supplementary Table 9). Neuropathologists were provided with a drop-down list containing the 102 methylation subtypes, which correspond directly to Hetairos's output classes, and were asked to choose and rank their top-3 diagnoses from it. The neuropathologists participating in the evaluation had prior experience with methylation classification and were thus familiar with the provided classes. Based on H&E-stained sections only, Hetairos's accuracy was consistently better than that of neuropathologists, who achieved an average top-1 accuracy of 0.30 (0.18–0.36) compared to Hetairos's 0.68 (see the additional metrics provided in Supplementary Table 5). This gap narrowed when assessing top-3 accuracy, which was 0.50 (0.31–0.70) for humans and 0.84 for Hetairos (Fig. 5a). Human evaluators often appeared to struggle with identifying the single best choice among a large number of granular classes, but they were able to provide a plausible set of diagnoses. While Hetairos provided a calibrated range of confidence levels, it consistently outperformed human accuracy across all confidence intervals. The performance gap between human evaluators and Hetairos narrowed slightly within Hetairos's lower confidence range (Fig. 5b).

When considering individual tumor subtypes, Hetairos generally outperformed humans for classes represented by more than ten cases in the training cohort (Fig. 5c). For rare tumor subtypes with fewer than ten cases in the training cohort, human pathologists performed similarly to Hetairos. For some diagnoses, such as metastatic melanoma and teratoma—which Hetairos struggled to diagnose—human diagnoses were correct in two out of three cases and one out of one case,




Fig. 6 | Hetairos assists in the pathological evaluation and resolution of molecularly inconclusive cases. **a**, Flowchart of diagnostic steps for CNS tumors in neuropathology. Following histological assessment of H&E slides, approximately 30% of the samples require further molecular testing. Among these, 2% are low-material samples and 10% are low-methylation-confidence samples for which diagnosis cannot be resolved using DNA methylation analysis. IHC, immunohistochemistry. **b**, Examples of H&E-stained sections and heatmaps corresponding to Hetairos's highest probability prediction (shown below each

image). Red-colored regions indicate areas that Hetairos identified as strongly indicative of the listed tumor class. **c**, Hetairos's predictive performance across different confidence intervals on low-methylation-confidence samples ($n = 50$ slides). **d**, Hetairos's predictive performance across different confidence intervals on low-material samples ($n = 96$ slides), with a stereotactic biopsy example shown on the left. Flowchart in **a** created in BioRender; Patel, A. <https://biorender.com/crmoidj> (2026).

respectively. Together, these results indicate that Hetairos is currently better at diagnosing all but the rarest types of tumors.

AI-assisted diagnosis reaches methylation-level accuracy in 12 min

Named after the Greek term for 'companion', Hetairos is designed to assist neuropathologists in diagnostic work. As mentioned previously,

the typical diagnostic workflow in neuropathology begins with a morphological assessment of an H&E section, followed by a series of immunohistochemical tests selected to narrow the differential diagnoses (Fig. 6a). Approximately 30% of cases cannot be resolved in terms of tumor classification and subtyping without advanced molecular testing. Most of these can be resolved by DNA methylation array analysis, whereas some require additional testing, such as DNA and RNA sequencing,




Fig. 7 | Prospective clinical evaluation of Hetairos ($n = 210$ slides). **a**, Sankey plot showing the diagnostic path for the prospective validation cohort and the performance of Hetairos on those samples. Obtaining Hetairos's predictions takes an average of 12 min once the scanned H&E slide is available. **b**, Comparison

between the results from Hetairos and those from the methylation classifier on prospective samples with low methylation scores. **c**, Classification accuracy in low-methylation-score cases concordant or discordant with Hetairos's high-confidence predictions.

to identify pathognomonic mutations or fusions. Some specimens are unsuitable for molecular analysis because of limited sample quantity or quality. Hetairos fits into this workflow as a tool to supplement the first-line method—that is, manual histopathological evaluation using H&E-stained FFPE slides. Owing to Hetairos's WHO 2021-compatible granularity and well-calibrated predictions, it is intended to be used as a triaging tool to efficiently guide further molecular analyses.

The report provided by Hetairos highlights tissue areas of the H&E slide that are most informative for diagnostic prediction and those that contribute least, both in a prediction map and with exemplary magnifications (Fig. 6b; see also the example reports in Extended Data Fig. 6 and Supplementary Table 10). These illustrations enable neuropathologists to review Hetairos's decision-making and may also guide the selection of optimal areas for extraction if further molecular testing is needed. For example, areas that are morphologically informative for the diagnosis of craniopharyngioma or meningioma are robustly separated from adjacent connective tissue.

Within the spectrum of glial morphology, pilocytic astrocytoma bulk tissue was clearly distinguished from the surrounding reactive gliosis (Fig. 6b). Similarly, Hetairos uniformly identified the prototypical histology of oligodendroglioma (Extended Data Fig. 6a). In astrocytoma, areas considered by Hetairos to be indicative of the second-best diagnosis, glioblastoma, coincided with microvascular

proliferation—a characteristic feature of both diagnoses and a criterion for grade 4 tumors (Extended Data Figs. 6b and 7a,b).

Further examples of intratumoral heterogeneity were observed in meningiomas, where Hetairos frequently identified regions assigned to the benign category within intermediate-group cases and vice versa (Extended Data Fig. 8a–d). The biological underpinning of the distinct grading classes found within the same tumor was supported by Ki-67 staining patterns (that is, weaker staining in areas predicted to be benign). Taken together, these examples illustrate that Hetairos has the potential to capture subtle yet clinically relevant and biologically meaningful histologies that exhibit intratumoral heterogeneity and pose diagnostic challenges.

Even advanced technologies such as methylation analysis may sometimes fail to provide a clear prediction on their own, thus necessitating additional testing (for example, for fusions or mutations). Within a cohort of 50 samples diagnosed solely based on a combination of molecular assays, Hetairos correctly predicted 27 cases, demonstrating superiority over methylation analysis in some scenarios (Fig. 6c). For 96 specimens in which methylation analysis could not be performed because of limited tissue, particularly stereotactic biopsy samples, Hetairos correctly predicted 76 cases (Fig. 6d). This highlights the robustness and predictive capability of Hetairos in specimens with limited tumor content (Extended Data Fig. 9a,b).




Fig. 8 | Risk stratification based on predictions by Hetairos. a, Analysis of medulloblastoma ($n = 165$ slides). Left, Kaplan–Meier analysis of the subgroups. MB_WNT, medulloblastoma, WNT activated; MB_SHH, medulloblastoma, SHH activated; MB_G3, medulloblastoma, group 3; MB_G4, medulloblastoma, group 4; non-MB, other CNS tumor types. Right, confusion matrix between Hetairos's predictions and methylation classes. **b**, Ependymoma subtypes ($n = 90$ slides). Left, Kaplan–Meier analysis. EPN_PFA, posterior fossa ependymoma, group PFA; EPN_ST_ZFTA_FUS, supratentorial ependymoma, ZFTA fusion positive; EPN_MPE, myxopapillary ependymoma; EPN_SPINE, spinal ependymoma; EPN_PFB, posterior fossa ependymoma, group PFB; non-EPN, other CNS tumor types.

Right, confusion matrix as in **a**. **c**, WHO-defined high-grade gliomas (HGGs) ($n = 98$ slides). Left, Kaplan–Meier curves. Right, confusion matrix for Hetairos's predictions and methylation classes. In **a–c**, shaded areas in Kaplan–Meier plots represent 95% confidence intervals. For the confusion matrices, high- and low-confidence predictions are indicated as pairs (n_{high} ; n_{low}) in each tile. **d**, Harrell's c-index for different predictor settings. Box plots show the median (center line), 25th–75th percentiles (box bounds) and $1.5 \times$ the interquartile range (whiskers). Each dot in the box plot represents the c-index for one of the ten outer cross-validation folds.

To assess the potential clinical utility of Hetairos, the algorithm was prospectively evaluated alongside routine diagnostics from August 1, 2024, to June 1, 2025, at the Department of Neuropathology at UKHD. All cases that required molecular testing and met the inclusion criteria were included without any further selection. During this time, Hetairos was used to predict a total of 210 cases (Fig. 7a and Supplementary Table 11). Its results were compared to independent integrated diagnoses established by a combination of morphological assessment, immunohistochemistry, methylation classification, next-generation sequencing panel and RNA sequencing. Hetairos predictions were not made available to the neuropathologist and did not influence diagnostic or treatment decisions.

On average, it takes 12 days from the receipt of the neurosurgical specimen to an integrated diagnosis. As illustrated in Fig. 7a, this corresponds to approximately 16 days for cases requiring molecular testing. Hetairos, running on consumer-grade hardware, took an average of 12 min to process a slide and generate the report. This indicates that, together with the time taken for staining and scanning, Hetairos substantially shortens the turnaround time, with results usually available within 24 h or up to 2 days after sample receipt, depending on fixation time. Among cases that could not be resolved by histology or immunohistochemistry alone, Hetairos yielded 63% high-confidence

predictions and 37% low-confidence predictions. Hetairos's top-1 predictions were found to agree with the eventual integrated diagnosis in 120 of 133 high-confidence cases (90.2%; Fig. 7a), highlighting Hetairos's ability to deliver near-methylation accuracy within a substantially shorter timeframe. For cases with high methylation scores and high confidence, Hetairos achieved an accuracy of 94.3% (100 of 106), while for those with low Hetairos confidence, the accuracy was 45.5% (35 of 77). In this subgroup with low methylation scores, Hetairos and the methylation classifier showed comparable accuracy against the integrated diagnosis (Fig. 7b). Notably, among the low-methylation-score cases that were concordant with Hetairos's high-confidence predictions, the accuracy reached 88.9% (16 of 18; Fig. 7c), further demonstrating how Hetairos can aid diagnostic decision-making when molecular results are inconclusive.

Granular tumor classification stratifies survival

Multiple studies have underscored the need for a granular classification of CNS tumors to reflect considerable differences in survival^{2,34–37}. To demonstrate the prognostic utility of Hetairos's detailed classification, we used data from 353 patients with CNS tumors in the MNP 2.0 trial², for whom digital H&E images, methylation classification and survival data are available.

Among these data, Hetairos classified 165 cases into one of the four WHO-defined subtypes of medulloblastoma: WNT activated, sonic hedgehog (SHH) activated, group 3 and group 4 (Fig. 8a). Compared to the methylation class, the accuracies were 89% and 51% for high- and low-confidence predictions, respectively. Despite some misclassification among low-confidence predictions, Cox proportional hazards models confirmed that Hetairos's subtypes exhibited notable differences in overall survival ($P = 0.03$). The 3-year overall survival rates were 58% for tumors classified as group 3 medulloblastoma, 81% for SHH-activated medulloblastoma, 88% for group 4 medulloblastoma and 100% for WNT-activated medulloblastoma. These results are in agreement with previous findings³⁸.

Similarly, Hetairos predicted 90 cases as five different WHO subtypes of ependymoma (Fig. 8b). The accuracy of high-confidence and low-confidence predictions was 100% and 48%, respectively. Overall survival among the predicted subtypes differed in the expected manner ($P = 0.07$). Group PFA posterior fossa ependymoma and ZFTA fusion-positive supratentorial ependymoma had poorer prognoses, with 3-year survival rates of 89% and 68%, respectively, compared to the other three ependymoma subtypes, all of which had 3-year survival rates of 100%.

Lastly, we applied Hetairos to classify samples histologically diagnosed as high-grade gliomas into more detailed subtypes. These subtypes were grouped into high- and low-risk categories based on independent prior knowledge² (Methods). Notwithstanding the challenges of accurately classifying glioma subtypes, the survival curves exhibited the expected trend of worse overall survival in high-risk groups (3-year survival: 38% versus 55%; $P = 0.2$; Fig. 8c). Additionally, a multivariate survival analysis confirmed that Hetairos provides stronger prognostic value than the clinical baseline alone, offering a more effective alternative in the absence of molecular testing (Fig. 8d).

Discussion

Here, we present Hetairos, an AI-based algorithm capable of diagnosing 102 types of CNS tumors from scanned H&E slides. Hetairos was trained and evaluated on more than 11,000 slides from 11 institutions across four continents. Crucial to Hetairos's applicability across cohorts are its realistic confidence estimates, which help judge its prediction accuracy. Depending on the cohort, Hetairos made high-confidence predictions in 50–70% of cases, and those predictions were found to be the correct diagnosis in nearly 90% of instances.

Current limitations of Hetairos include lower confidence and accuracy on rare tumor subtypes, as well as reduced confidence on new cohorts. Both limitations can be mitigated with larger and more diverse training cohorts, as demonstrated by our subsampling experiments (Extended Data Fig. 10a,b and Supplementary Table 12), in which the model's accuracy increased logarithmically with training size. Hetairos's performance on external cohorts could be further improved by retraining on data from all cohorts. Further methodological refinements that simulate the effects of different scanners and slide preparation are also likely to improve the algorithm's performance on new datasets. Moreover, fine-tuning foundation models used for feature extraction—either with cohort-specific data or through parameter-efficient strategies such as LoRA³⁹—may further enhance task-specific performance. Currently, Hetairos works with H&E-stained sections of FFPE tissues, as these constitute the diagnostic standard. However, it is conceivable to train extensions that would also work with fresh-frozen tissues, as we observed a decline in model performance on frozen sections.

The utility of Hetairos seems manifold. The ability to provide precise diagnoses with clinically relevant granularity using routine diagnostic material has the potential to enable widespread application. The 2021 WHO classification of CNS tumors requires additional molecular diagnostic tools to cover the full spectrum. This dependence on advanced techniques may restrict comprehensive evaluations to

well-resourced healthcare systems⁸. The cost of methylation analysis varies but is approximately €400 per case. While Hetairos uses digital images that require a microscopy slide scanner, such devices are more accessible than those used for methylation profiling. Considering computing resources, energy consumption and other maintenance costs, the estimated average cost per case for running Hetairos is approximately €1–2. Moreover, future Hetairos extensions may enable the use of photographs taken with smartphone adapters for basic microscopes.

Even well-equipped laboratories can benefit from Hetairos, as it helps reduce the time to diagnosis and enables the faster initiation of treatment. We envision Hetairos as a scalable tool for effective diagnostic triaging that may help reduce the number of required molecular tests, thereby lowering costs and freeing up resources. For rare tumor types exhibiting lower accuracies, Hetairos tends to assign low confidence scores, prompting the prioritization of these cases for molecular testing, which is indispensable for their diagnosis. Hetairos can also help establish diagnoses in cases where molecular tests are inconclusive or when there is insufficient material for methylation analysis. The ability to annotate scanned slide images and overlay areas suggestive of a limited set of differential diagnoses guides histopathological assessment and may help train histopathologists to recognize the subtle features that distinguish similar subtypes.

In summary, Hetairos demonstrates the remarkable potential of digital pathology to provide swift and accessible methods for diagnosing tumors with a level of granularity that would otherwise require considerable resources. While Hetairos has—and is aware of—its limitations, these are likely to be overcome in future versions trained on larger and more diverse cohorts and with methodological refinements.

Methods

Ethics and inclusion statement

Ethics approval for this study was granted by the Ethics Committee of the Medical Faculty of the University of Heidelberg (S-649/2021). Slides from University College London were obtained under BRAIN UK ethics approval (22/015). Informed consent was waived for this study, and no compensation was provided to participants. Participant selection was determined solely by the availability of histopathology images and corresponding diagnoses. No exclusions were made based on race, ethnicity, sex, gender or other social factors.

Patient cohorts

Hetairos was developed using 6,115 scanned whole-slide images of H&E-stained CNS tumors from 4,961 cases at UKHD. Slides were scanned using a Leica Aperio AT2 slide scanner at a maximum magnification of 40×. The dataset was divided into 4,803 slides for training, 1,102 slides for internal validation and 210 slides reserved for comparative testing with neuropathologists, with stratification by tumor subtype. There was no overlap of cases between the training and validation sets. Methylation profiles for each tumor were available and used to generate predictions with version 12.8 of the Molecular Neuropathology methylation classifier (<https://www.molecularneuropathology.org>), which is fully compatible with the Illumina EPIC v1 and v2 (850K) platforms, as well as other sequencing-based platforms, ensuring its continued applicability. A total of 184 methylation-based subclasses were represented in the dataset. The internal validation and comparative testing sets included only samples with methylation scores >0.8. The training set comprised samples with methylation scores ranging from 0.3 to 1. Samples with low methylation scores (<0.8) were included in the training set if the predicted methylation class was consistent with auxiliary molecular findings, such as mutations, fusions or copy number alterations. Methylation classes were aggregated into 102 subtypes to preserve clinically relevant categories while merging those with no established clinical relevance, such as the various subtypes of glioblastoma, which have been shown to display intratumoral variance^{40,41}.

In addition to the 20% of the UKHD cohort used as the internal validation set, ten external validation cohorts were analyzed. Methylation classes were used as the ground truth for cohorts with matched methylation classification data. In line with the recommended cutoffs, cases with methylation class scores (MC scores) > 0.8 were used and reported in the main text. Cohorts with matched methylation classes were as follows: University College London, UK ($n = 857$; MC score > 0.8: $n = 535$); University Cancer Center Frankfurt, Germany ($n = 73$; MC score > 0.8: $n = 63$); Groupe Hospitalier Universitaire Paris Psychiatrie & Neurosciences, France ($n = 164$; MC score > 0.8: $n = 134$); Justus Liebig University Giessen, Germany ($n = 217$; MC score > 0.8: $n = 125$); Charité Berlin, Germany ($n = 77$; MC score > 0.8: $n = 77$); and The Cancer Genome Atlas (TCGA; $n = 862$; MC score > 0.8: $n = 732$). Cohorts without matched methylation classes were Chongqing Medical University, China ($n = 70$); AC Camargo Cancer Center, Brazil ($n = 30$); Pontificia Universidad Católica de Chile, Chile ($n = 30$; MC score > 0.8: $n = 30$); and the publicly available EBRAINS DBTA ($n = 3,110$). Final integrated diagnoses were used to infer labels for the external validation datasets from Chongqing Medical University and AC Camargo Cancer Center. Histopathological diagnoses provided in the EBRAINS DBTA dataset were matched to the model's classification scheme where applicable. The DBTA dataset was accessed through the EBRAINS DBTA data portal (<https://ebrains.eu>, <https://doi.org/10.25493/WQ48-ZGX>)⁴². Whole-slide images and matched methylation profiles for the TCGA-LGG (low-grade glioma) and TCGA-GBM (glioblastoma) cohorts were downloaded in October 2020 from the Genomic Data Commons data portal^{43,44}. Stereotactic biopsy samples and samples from the MNP 2.0 cohort without sufficient material for methylation array analysis or with low methylation scores were included if compatible integrated diagnoses could be issued using other molecular markers, such as characteristic mutations or fusions^{2,9}. A total of 353 CNS tumor samples with corresponding H&E images and survival data from the MNP 2.0 cohort were included in the survival difference analysis. These samples primarily consisted of medulloblastomas, ependymomas and high-grade gliomas.

Hetairos framework

The Hetairos framework consists of three main steps: (1) slide image preprocessing, (2) feature extraction, and (3) feature aggregation and final prediction. Each step is outlined in detail below.

In the preprocessing step, we began by identifying tissue in the slide images. Each whole-slide image was initially segmented to identify tissue regions using hysteresis thresholding at a downsampled resolution. Additionally, we masked ink-covered regions using a manually defined set of colors. Tissue-containing areas were then divided into nonoverlapping tiles of 256×256 pixels at a nominal magnification of $20\times$, corresponding to $0.5 \mu\text{m}$ per pixel. Finally, we used Sobel image gradient-based filtering to exclude blurred and low-tissue-content tiles.

Subsequently, 1,536-dimensional tile feature representations were extracted using the pretrained Prov-GigaPath model, which is based on a ViT-G/14 vision transformer⁴⁵ pretrained with the DINOv2 framework⁴⁶. The previously obtained tiles were resized to 224×224 pixels, resulting in $17.5\times$ -magnification tiles that were then processed using Prov-GigaPath. Notably, other histopathology foundation models could be used as alternatives; in our experiments, UNI performed similarly. After feature extraction, each slide image is represented as an $n \times 1,536$ matrix, where n represents the number of tiles in the slide.

The feature aggregation step condenses all tile-level features into a single slide-level representation and makes the final prediction by dynamically selecting the most informative tiles. We used a custom-modified TransMIL model, an embedding-based multiple-instance learning (MIL) method for aggregation. The TransMIL architecture consists of two consecutive transformer blocks with Nyström attention⁴⁷, replacing the standard scaled dot-product attention to reduce computational complexity. As a regularization method, we randomly divided the slide matrix $H \in \mathbb{R}^{n \times 1,536}$ into m submatrices,

$H_i \in \mathbb{R}^{n_i \times 1,536}$ ($\sum_{i=1}^m n_i = n$), which were then separately processed by the aggregator. After applying the multihead Nyström attention (MSA) twice, the resulting embedding matrix can be represented as $H_i^{\text{attn}} = \text{MSA}(\text{MSA}(H_i)) = [H_i^{\text{cls}}; H_i^1; \dots; H_i^m]$, where $H_i^{\text{cls}} \in \mathbb{R}^{1 \times 512}$ is the computed class token for submatrix H_i , and H_i^j represents the weighted tile embeddings. The slide embedding was subsequently constructed by concatenating the class token from each submatrix, denoted as $h_{\text{slide}} = [h_1^{\text{cls}}, \dots, h_m^{\text{cls}}]$, where $h_{\text{slide}} \in \mathbb{R}^{1 \times (m \times 512)}$. Each submatrix class token h_i^{cls} was processed through a multilayer perceptron (MLP) tailored for localized predictions, while the slide embedding h_{slide} was fed into a separate MLP constructed for slide-level predictions. Both outputs were supervised using a unified label, leveraging cross-entropy loss to enforce alignment between local and global predictions and to enhance predictive consistency across scales. Optionally, the patient's age and the anatomical location of the tumor (extracranial, infratentorial, intra- or periventricular, intra- or suprasellar, pineal, spinal, or supratentorial) can be specified to enhance prediction accuracy. The age is encoded as a 32-dimensional vector using sinusoidal positional encoding functions, while the location is one-hot encoded. These two additional features are concatenated with the class token of each submatrix before being processed by the output MLP.

To further accentuate the differences between the features of various tumor types, feature templates for each tumor class were constructed in the latent space to regulate the interclass feature distances. Specifically, the mean reweighted tile embeddings from each submatrix serve as representation features in the latent space, which is $z_i = \frac{1}{n_i} \sum_{j=1}^{n_i} h_i^j$. The corresponding tumor class template feature Z_k is represented as the exponential moving average of the representation features for tumor samples with class k given $Z_k^{t+1} = (1 - \alpha)Z_k^t + \alpha z_i$, where sample i belongs to class k . Thus, a contrastive loss is formulated based on the class template and representation features in the latent space, as follows:

$$L_{\text{cl}} = \sum_{i=1, i \in \text{class } k}^n \left[\left(1 - \frac{z_i \cdot Z_k}{\|z_i\| \|Z_k\|} \right) + \sum_{l \neq k} \min \left(\frac{z_i \cdot Z_l}{\|z_i\| \|Z_l\|}, \epsilon \right) \right]$$

Combined with the cross-entropy (CE) loss for classification, the overall loss function is defined as follows:

$$L = \text{CE}(\hat{y}, y) + \frac{1}{m} \sum_{i=1}^m \text{CE}(\hat{y}_i, y) + \beta L_{\text{cl}}$$

where $\hat{y}$ denotes the slide-level prediction, $\hat{y}_i$ is the local prediction derived from submatrix H_i , and y corresponds to the class probability vector estimated by version 12.8 of the Molecular Neuropathology methylation classifier.

Data augmentations are widely used to prevent overfitting on training samples. However, directly applying traditional image-level augmentations to tiles in an online manner is computationally expensive within the MIL framework, as the tiles must be passed through the feature extractor each time. To avoid this, we applied augmentation to the training samples in the tile embedding space. We used Mixup⁴⁸ on the feature embeddings generated by the pretrained feature extractor. That is, given the slide embedding matrix H with label k , and matrix H' with label k' from another sample, the augmented sample is computed as $\gamma H + (1 - \gamma)H'$, with the corresponding label $\gamma k + (1 - \gamma)k'$. Note that the tile numbers of the two samples are aligned by downsampling or upsampling before mixing. This augmentation method enhances the diversity of training samples with minimal computational cost.

For inference, we used a deep ensemble to improve predictive accuracy and model robustness by combining the outputs of multiple independently trained models. In this case, ten copies of the aggregator were trained using different seeds. The probability vectors output by the ten models were then averaged to obtain the final predicted probabilities for each tumor subtype. The use of deep ensembles is known

to enhance performance, especially for infrequent classes⁴⁹, and to be beneficial for improving the calibration of output probabilities³⁰.

The automatically generated reports include heatmaps showing which regions of the slide are predicted to be a given tumor type. This is done by processing small local regions of 5×5 tiles in a sliding window fashion and then composing the local predictions into the global prediction map.

Implementation details

The Hetairos model was implemented with Python 3.10.15 using the PyTorch Lightning (version 2.0.8) and PyTorch (version 2.5.1) frameworks. The libraries mainly involved were OpenSlide (version 1.2.0), OpenCV (version 4.8.0), Timm (version 1.0.8), Pillow (version 9.5.0), NumPy (version 1.24.4), pandas (version 2.0.3), h5py (version 3.9.0) and Wandb (version 0.18.7). During training, the Hetairos aggregator weights were initialized with a random seed, and a batch size of 1 was used. We used a Lookahead optimizer with a learning rate of 1×10^{-5} and a weight decay of 1×10^{-5} to optimize the model weights, with an early stopping threshold set at 10 epochs. The number of random submatrices m was set to 3. The margin parameter ε in the contrastive loss was set to 0.2, and its corresponding weight coefficient β was set to 20. The smoothing factor α used for calculating the exponential moving average was dynamically adjusted to 0.5, 0.75 and 0.99 during epochs 0–3, 6–9 and 9 onward, respectively. The data augmentation probability was set to 0.7, while age and anatomical location data were randomly omitted at a rate of 0.3. The training and testing of Hetairos can be performed on consumer-grade hardware, such as a single GPU with at least 11 GB of graphics memory (for example, a GeForce RTX 2080 Ti). There are no stringent requirements for the CPU; however, a higher thread count may enhance the efficiency of tiling during the preprocessing step. Additionally, a system with more than 16 GB of RAM is recommended.

Neuropathologists versus Hetairos

A total of 210 whole-slide images were sent on portable hard drives to five board-certified neuropathologists. Each class represented in the dataset comprised one to three slides. The neuropathologists were asked to select up to three diagnoses from a drop-down list based on their level of confidence in each diagnosis. No additional information about the cases, beyond the H&E slide images, was provided to the neuropathologists or the model.

Risk groups for survival stratification

For the Hetairos risk groups, model-predicted classes were used to establish the high- and low-risk groups for high-grade gliomas based on prior knowledge². The high-risk group consisted of the following tumors: diffuse midline glioma, H3 K27 altered; diffuse hemispheric glioma, H3 G34 mutant; high-grade diffuse glioma of the midline/posterior fossa, H3/IDH wild-type; diffuse pediatric-type high-grade glioma; and glioblastoma, IDH wild-type. The low-risk group included the following tumors: astrocytoma, IDH mutant; pleomorphic xanthoastrocytoma; infant-type hemispheric glioma; CNS neuroblastoma, FOXR2 altered; HGAP; pilocytic astrocytoma; ganglioglioma; diffuse glioma, MYB or MYBL1 altered; and diffuse leptomeningeal glioneuronal tumor. Predictions falling outside the defined categories were classified as ‘unknown’. For the molecular risk group defined by Sturm et al.², the intermediate-risk group was merged into the low-risk group to facilitate analysis.

Statistics and reproducibility

No statistical method was used to predetermine the sample size; all available cases from participating centers that met the inclusion criteria were included. No data were excluded from the analysis. The internal dataset was split into training (80%) and validation (20%) sets using random patient-level assignment. External validation cohorts were not

randomized. Data collection and analysis were not performed blind to the conditions of the experiments. Data distribution was not assumed to be normal for the main classification performance analyses, which were based on categorical outcomes and nonparametric summary metrics, including top-1 accuracy, top-3 accuracy and confidence-stratified accuracy. Differences in overall survival across Hetairos-predicted subtypes were assessed using a Cox proportional hazards model, with statistical significance determined by the likelihood ratio test, which does not assume a specific distribution of the survival data. The relevant model assumptions are proportional hazards, independent observations and noninformative censoring. Hetairos is a deterministic model with fixed weights; given identical inputs, its predictions are fully reproducible.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Restrictions apply to the availability of datasets used for training and internal validation, which were collected retrospectively under institutional and ethical approval and are, therefore, not publicly available. These datasets comprise routine clinical histopathology and DNA methylation data collected as part of the standard diagnostic workup and were not generated for research purposes; therefore, they are not eligible for public redistribution. Requests for these datasets should be directed to one of the corresponding authors (F.S., felix.sahm@med.uni-heidelberg.de). Requests will be reviewed within 4 weeks and evaluated according to institutional and departmental policies regarding patient privacy and intellectual property obligations. External validation datasets were obtained under data sharing agreements with the respective contributing institutes and cannot be redistributed. Access requests should be directed to the respective contributing institutions. Publicly available datasets used in this study included TCGA-LGG, TCGA-GBM and the Digital Brain Tumour Atlas (EBRAINS DBTA). Additional data supporting the findings and reproducibility of this study are available at <https://github.com/gerstung-lab/Hetairos>. Source data are provided with this paper.

Code availability

The code for Hetairos training and validation, data preprocessing and figure reproduction is publicly available at <https://github.com/gerstung-lab/Hetairos>.

References

1. Capper, D. et al. DNA methylation-based classification of central nervous system tumours. *Nature* **555**, 469–474 (2018).
2. Sturm, D. et al. Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. *Nat. Med.* **29**, 917–926 (2023).
3. Jaunmuktane, Z. et al. Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. *Acta Neuropathol. Commun.* **7**, 24 (2019).
4. Capper, D. et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. *Acta Neuropathol.* **136**, 181–210 (2018).
5. White, C. L. et al. Implementation of DNA methylation array profiling in pediatric central nervous system tumors: the AIM BRAIN project: an Australian and New Zealand Children's Haematology/Oncology Group study. *J. Mol. Diagn.* **25**, 709–728 (2023).
6. Karimi, S. et al. The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care. *Clin. Epigenetics* **11**, 185 (2019).

7. Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro Oncol.* **23**, 1231–1251 (2021).
8. Horbinski, C., Berger, T., Packer, R. J. & Wen, P. Y. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. *Nat. Rev. Neurol.* **18**, 515–529 (2022).
9. Alhalabi, O. T., Sahm, F., Unterberg, A. W. & Jakobs, M. The molecular diagnostic yield of frame-based stereotactic biopsies in the age of precision neuro-oncology: a cross-sectional study. *Acta Neurochir. (Wien)* **165**, 2479–2487 (2023).
10. Wick, W. et al. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. *Neuro Oncol.* **21**, 95–105 (2019).
11. Vermeulen, C. et al. Ultra-fast deep-learned CNS tumour classification during surgery. *Nature* **622**, 842–849 (2023).
12. Deacon, S. et al. ROBIN: a unified nanopore-based sequencing assay integrating real-time, intraoperative methylome classification and next-day comprehensive molecular brain tumour profiling for ultra-rapid tumour diagnostics. *Neuro Oncol.* **27**, 2035–2046 (2025).
13. Patel, A. et al. Prospective, multicenter validation of a platform for rapid molecular profiling of central nervous system tumors. *Nat. Med.* **31**, 1567–1577 (2025).
14. Bertero, L., Mangherini, L., Ricci, A. A., Cassoni, P. & Sahm, F. Molecular neuropathology: an essential and evolving toolbox for the diagnosis and clinical management of central nervous system tumors. *Virchows Arch.* <https://doi.org/10.1007/s00428-023-03632-4> (2024).
15. Ehle, A. et al. Deep learning in cancer pathology: a new generation of clinical biomarkers. *Br. J. Cancer* **124**, 686–696 (2021).
16. Shmatko, A., Ghaffari Laleh, N., Gerstung, M. & Kather, J. N. Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. *Nat. Cancer* **3**, 1026–1038 (2022).
17. Wagner, S. J. et al. Transformer-based biomarker prediction from colorectal cancer histology: a large-scale multicentric study. *Cancer Cell* **41**, 1650–1661 (2023).
18. Song, A. H. et al. Artificial intelligence for digital and computational pathology. *Nat. Rev. Bioeng.* **1**, 930–949 (2023).
19. Jin, D. et al. Teacher–student collaborated multiple instance learning for pan-cancer *PDL1* expression prediction from histopathology slides. *Nat. Commun.* **15**, 3063 (2024).
20. Fu, Y. et al. Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis. *Nat. Cancer* **1**, 800–810 (2020).
21. Chen, R. J. et al. Towards a general-purpose foundation model for computational pathology. *Nat. Med.* **30**, 850–862 (2024).
22. Xu, H. et al. A whole-slide foundation model for digital pathology from real-world data. *Nature* **630**, 181–188 (2024).
23. Vorontsov, E. et al. A foundation model for clinical-grade computational pathology and rare cancers detection. *Nat. Med.* **30**, 2924–2935 (2024).
24. Wang, X. et al. A pathology foundation model for cancer diagnosis and prognosis prediction. *Nature* **634**, 970–978 (2024).
25. Hoang, D.-T. et al. Prediction of DNA methylation-based tumor types from histopathology in central nervous system tumors with deep learning. *Nat. Med.* **30**, 1952–1961 (2024).
26. Hewitt, K. J. et al. Direct image to subtype prediction for brain tumors using deep learning. *Neurooncol. Adv.* **5**, vdad139 (2023).
27. Li, Z. et al. Vision transformer-based weakly supervised histopathological image analysis of primary brain tumors. *iScience* **26**, 105872 (2023).
28. Wang, W. et al. Neuropathologist-level integrated classification of adult-type diffuse gliomas using deep learning from whole-slide pathological images. *Nat. Commun.* **14**, 6359 (2023).
29. Schumann, Y. et al. Morphology-based molecular classification of spinal cord ependymomas using deep neural networks. *Brain Pathol.* **34**, e13239 (2024).
30. Shao, Z. et al. TransMIL: transformer based correlated multiple instance learning for whole slide image classification. In *35th Conference on Neural Information Processing Systems (NeurIPS 2021)* <https://proceedings.neurips.cc/paper/2021/file/10c272d06794d3e5785d5e7c5356e9ff-Paper.pdf> (2021).
31. McInnes, L., Healy, J. & Melville, J. UMAP: uniform manifold approximation and projection for dimension reduction. Preprint at <https://arxiv.org/abs/1802.03426> (2018).
32. Vaidya, A. et al. Demographic bias in misdiagnosis by computational pathology models. *Nat. Med.* **30**, 1174–1190 (2024).
33. Perez-Lopez, R., Ghaffari Laleh, N., Mahmood, F. & Kather, J. N. A guide to artificial intelligence for cancer researchers. *Nat. Rev. Cancer* **24**, 427–441 (2024).
34. Pohl, L. C. et al. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas. *Acta Neuropathol.* **147**, 24 (2024).
35. Mynarek, M. et al. Nonmetastatic medulloblastoma of early childhood: results from the prospective clinical trial HIT-2000 and an extended validation cohort. *J. Clin. Oncol.* **38**, 2028–2040 (2020).
36. Sahm, F. et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. *Lancet Oncol.* **18**, 682–694 (2017).
37. Pajtler, K. W. et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. *Cancer Cell* **27**, 728–743 (2015).
38. Taylor, M. D. et al. Molecular subgroups of medulloblastoma: the current consensus. *Acta Neuropathol.* **123**, 465–472 (2012).
39. Hu, E. J. et al. LoRA: low-rank adaptation of large language models. In *International Conference on Learning Representations* <https://openreview.net/pdf?id=nZeVfKeeFYf9> (ICLR, 2022).
40. Wenger, A. et al. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification. *Neuro Oncol.* **21**, 616–627 (2019).
41. Singh, O. et al. EPCO-26. Intratumoral heterogeneity of GBM identified and characterized by a multisampling approach and methylation profiling. *Neuro Oncol.* **25**, v129 (2023).
42. Roetzer-Pejrimovsky, T. et al. The Digital Brain Tumour Atlas, an open histopathology resource. *Sci. Data* **9**, 55 (2022).
43. Grossman, R. L. et al. Toward a shared vision for cancer genomic data. *N. Engl. J. Med.* **375**, 1109–1112 (2016).
44. Ceccarelli, M. et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. *Cell* **164**, 550–563 (2016).
45. Dosovitskiy, A. et al. An image is worth 16×16 words: transformers for image recognition at scale. In *International Conference on Learning Representations* <https://openreview.net/pdf?id=YicbFdNTTy> (ICLR, 2021).
46. Oquab, M. et al. DINOv2: learning robust visual features without supervision. In *Transactions on Machine Learning Research* <https://openreview.net/pdf?id=a68SUt6zFt> (2024).
47. Xiong, Y. et al. Nyströmformer: a Nyström-based algorithm for approximating self-attention. *Proc. AAAI Conf. Artif. Intell.* **35**, 14138–14148 (2021).
48. Zhang, H., Cisse, M., Dauphin, Y. N. & Lopez-Paz, D. Mixup: beyond empirical risk minimization. In *International Conference on Learning Representations* <https://openreview.net/pdf?id=r1Ddp1-Rb> (ICLR, 2018).

49. Ko, W.-Y., D'souza, D., Nguyen, K., Balestrieri, R. & Hooker, S. FAIR-ensemble: when fairness naturally emerges from deep ensembling. Preprint at <https://arxiv.org/abs/2303.00586> (2023).
50. Ovadia, Y. et al. Can you trust your model's uncertainty? Evaluating predictive uncertainty under dataset shift. In *33rd Conference on Neural Information Processing Systems (NeurIPS 2019)* https://proceedings.neurips.cc/paper_files/paper/2019/file/8558cb408c1d76621371888657d2eb1d-Paper.pdf (2019).

Author contributions

The study was led by F.S. and M.G. D.J., A.S. and A.P. developed the Hetairos model and analyzed all data. X.B. assisted with model development. M.G., F.S., D.J., A.S. and A.P. wrote the manuscript, with help from S.R. D.M. and K.E. participated in performing tumor classification using H&E histology alone and histology with Hetairos assistance. R.R., R.B., L.F., P.S., S.H., D. Schrimpf, K.G., H.B., S.L.N.M., M.S., F.E.H., A.K.S., F.K., A.H., G.R., F.Z., O.T.A., S.I., J.S., D.A., B.W., P.P.L., B.S., O.A., D. Sturm, D.R., P.W., A.W., F.L.H., I.B., C.D., M.J., C.H.-M., S.M.K., W.W., D.T.W.J., S.M.P., M.A.-H., Y.H., F.D'A.C., L.S., L.B., T.A., A.T.-E., P.V., H.D., P.Z., R.G., S.B. and A.v.D. helped with data collection. All authors approved the manuscript.

Funding

M.G. and D.J. are supported by a grant from the Rolf M. Schwiete Foundation, Mannheim. F.E.H. is supported by a fellowship from the Heidelberg College of Neuro-Oncology, funded by the Else Kröner Fresenius Foundation (EKFS). F.K. is funded by the Dieter Schwarz Stiftung in Heilbronn. L.B. is supported by a research grant from Fondazione Ricerca Molinette ETS, Turin, Italy. The MNP 2.0 study was supported by the German Childhood Cancer Foundation (DKS 2015.01). D.M. is supported by the SNF. D. Sturm is supported by an Else Kröner Excellence Fellowship. This study was supported by CRC/SFB 1389 UNITE Glioblastoma. F.S. is supported by a grant from the Rolf M. Schwiete Foundation, Mannheim. Open access funding provided by Deutsches Krebsforschungszentrum (DKFZ).

Competing interests

D. Schrimpf, M.S., D.T.W.J., S.M.P., A.v.D. and F.S. are shareholders in and cofounders of Heidelberg Epignostix GmbH. A.P. and M.S. have been full-time employees of Heidelberg Epignostix GmbH since December and July 2024, respectively. D. Schrimpf has been a part-time employee of Heidelberg Epignostix GmbH since November

2024. S.I. is a consultant for Brainlab AG, Icotec AG and Carl Zeiss Meditec AG and has received past honoraria from Nexstim AG. S.M.K. is a consultant for Brainlab AG, Ulrich Medical and Need Inc.; a shareholder of Need Inc.; and has received honoraria from Nexstim Plc, Spineart Deutschland GmbH, Medtronic AG and Carl Zeiss Meditec AG. The other authors declare no competing interests.

Additional information

Extended data is available for this paper at <https://doi.org/10.1038/s43018-026-01186-3>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s43018-026-01186-3>.

Correspondence and requests for materials should be addressed to Felix Sahm or Moritz Gerstung.

Peer review information *Nature Cancer* thanks Todd Hollon, Craig Horbinski and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.


© The Author(s) 2026

Darui Jin (晋达睿) ^{1,2,45}, **Artem Shmatko** ^{1,3,45}, **Areeba Patel**^{1,4,5,6,45}, **Samuel Rutz** ^{1,7}, **Lukas Friedrich** ^{4,5}, **Rouzbah Banan** ^{4,5}, **Ramin Rahmzade**^{4,5}, **Philipp Sievers** ^{4,5}, **Stefan Hamelmann**^{4,5}, **Daniel Schrimpf**^{4,5}, **Kirsten Göbel** ^{4,5}, **Henri Bogumil**^{4,5}, **Sybren L. N. Maas** ^{8,9}, **Martin Sill** ^{6,10}, **Felix E. Hinz**^{4,5}, **Abigail K. Suwala**^{4,5}, **Felix Keller**^{4,5,7}, **Antje Habel** ^{4,5}, **Gleb Rukhovich**¹, **Ferdinand Zettl**^{4,5}, **Obada T. Alhalabi**¹¹, **Sebastian Ille**¹¹, **Jannik Sehring** ¹², **Daniel Amsel**¹², **Benedikt Wiestler** ^{13,14}, **Pedro Piovesan Lago** ¹⁵, **Bogdana Suchorska**¹¹, **Olfat Ahmad** ⁶, **Dominik Sturm** ^{6,16,17}, **David Reuss**^{4,5}, **Pieter Wesseling**^{18,19}, **Adelheid Wöhrer** ^{20,21}, **Frank L. Heppner** ^{22,23}, **Ingmar Blümcke**²⁴, **Claire Delbridge**²⁵, **Martin Jakobs**^{11,26}, **Christel Herold-Mende** ¹¹, **Sandro M. Krieg** ¹¹, **Wolfgang Wick** ^{27,28}, **David T. W. Jones** ^{6,16,29}, **Stefan M. Pfister** ^{6,10,17,29}, **Maysa Al-Hussaini** ^{30,31}, **Yanghai Hou**^{32,33}, **Felipe D'Almeida Costa** ^{15,34}, **Leonille Schweizer**^{35,36,37}, **Luca Bertero** ³⁸, **Till Acker** ¹², **Arnault Tauziède-Espariat**^{39,40}, **Pascale Varlet**^{39,40}, **Doron Merkler**^{41,42}, **Kristof Egervari**^{41,42}, **Hildegard Dohmen**¹², **Pablo Zoroquian**⁴³, **Roger Gejman**⁴³, **Sebastian Brandner** ⁴⁴, **Xiangzhi Bai** ², **Andreas von Deimling** ^{4,5}, **Felix Sahm** ^{4,5,6} ✉ & **Moritz Gerstung** ^{1,7} ✉

¹Division of AI in Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. ²Image Processing Center, Beihang University, Beijing, China.


³Faculty of Biosciences, Heidelberg University, Heidelberg, Germany. ⁴Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany. ⁵Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany. ⁶Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany. ⁷Faculty of Mathematics and Computer Science, Heidelberg University, Heidelberg, Germany. ⁸Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. ⁹Department of Pathology, Brain Tumor Center, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. ¹⁰Division of Pediatric Neurooncology,

German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany. ¹¹Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany. ¹²Institute of Neuropathology, Justus Liebig University Giessen, Giessen, Germany. ¹³AI for Image-Guided Diagnosis and Therapy, School of Medicine and Health, Technical University of Munich, Munich, Germany. ¹⁴Munich Center for Machine Learning (MCML), Munich, Germany. ¹⁵AC Camargo Cancer Center, São Paulo, Brazil. ¹⁶Division of Pediatric Glioma Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. ¹⁷Department of Pediatric Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany. ¹⁸Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. ¹⁹Department of Pathology, Amsterdam University Medical Centers/VUmc, Amsterdam, The Netherlands. ²⁰Division of Neuropathology and Neurochemistry, Department of Neurology, Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria. ²¹Institute of Neuropathology and Neuromolecular Pathology, Medical University of Innsbruck, Innsbruck, Austria. ²²Department of Neuropathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany. ²³German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, Berlin, Germany. ²⁴Department of Neuropathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. ²⁵Institute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany. ²⁶Division for Stereotactic Neurosurgery, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany. ²⁷Neurology Clinic, University Hospital Heidelberg, Heidelberg, Germany. ²⁸Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany. ²⁹National Center for Tumor Diseases (NCT), Heidelberg, Germany. ³⁰Department of Cell Therapy and Applied Genomics, King Hussein Cancer Center, Amman, Jordan. ³¹Department of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan. ³²Department of Pathology, Center for Molecular Medicine Testing, College of Basic Medicine, Chongqing Medical University, Chongqing, China. ³³Center for Medical Epigenetics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China. ³⁴DASA Laboratories, São Paulo, Brazil. ³⁵Edinger Institute, Institute of Neurology, University of Frankfurt am Main, Frankfurt am Main, Germany. ³⁶German Cancer Consortium (DKTK) Partner Site Frankfurt/Mainz and German Cancer Research Center (DKFZ), Heidelberg, Germany. ³⁷Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany. ³⁸Department of Medical Sciences, University of Turin, Turin, Italy. ³⁹Department of Neuropathology, Sainte-Anne Hospital, Paris, France. ⁴⁰Inserm, UMR 1266, IMA-Brain, Institut de Psychiatrie et Neurosciences de Paris, Paris, France. ⁴¹Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland. ⁴²Division of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland. ⁴³Pathology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. ⁴⁴Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK. ⁴⁵These authors contributed equally: Darui Jin, Artem Shmatko, Areeba Patel. ✉e-mail: felix.sahm@med.uni-heidelberg.de; moritz.gerstung@dkfz.de




Extended Data Fig. 1 | Class-wise accuracy comparison between hierarchical models and Hetairos within different tumour superfamilies. a-f, class-wise accuracy within the families of adult-type diffuse gliomas, low-grade glial/glioneuronal/neuroepithelial tumours, ependymal tumours, paediatric-type diffuse high-grade gliomas, meningioma and medulloblastoma. **Hierarchy s1:** We first applied the Hetairos to predict the subtype probabilities for each sample. Based on the predefined mapping between subtypes and

superfamilies, we inferred the corresponding predicted superfamily. Within this predicted superfamily, the final subtype was determined as the class with the highest probability. **Hierarchy s2:** Using the same hyperparameters as the original Hetairos, we first trained a model to classify 34 tumor superfamilies. Subsequently, separate subtype classification models were trained and validated within each individual superfamily.




Extended Data Fig. 2 | Oversampling and color space augmentation. **a**, Number of added samples per class for oversampling. The number of added samples to each class is proportional to the original sample size. **b**, Difference in per-class accuracy between models trained with and without oversampling. Classes on the x-axis are arranged in descending order of the training sample size. **c**, Examples of color jittering augmentation applied to tiles. Each slide in the training set was augmented using random transformations. **d**, Representative tiles used as reference for stain normalization. **e**, Difference versions of normalized tile

views. The Macenko Method is applied in the stain normalization. **f**, Examples of random stain transformation applied to tiles. Random perturbations were introduced to the concentration parameters to get the augmented views. **g**, Top-1 and top-3 accuracy on the internal validation for different augmented models. Baseline: the model trained on the dataset without any augmentations. **h**, Difference in class-wise accuracy between models trained with color space augmentations and the baseline model.



Extended Data Fig. 3 | Confusion matrix for external validation by Hetairos. The matrix provides a comprehensive view of classification accuracy across 72 CNS tumour subtypes (classes with sample size > 1), with the vertical axis representing the methylation classes and the horizontal axis the predicted


classes. Each cell displays the percentage of cases in each methylation class classified as each predicted class. Rectangle boxes group classes that belong to the same superfamily. The sample size of each class is listed on the right side.



Extended Data Fig. 4 | Color space distribution of different data centers.


a, Average R/G/B values for samples from different centers. Each center is represented by three bars from left to right, corresponding to the average values of the R, G, and B channels, respectively. The color of each bar reflects the RGB

values of the respective center. **b**, PCA-based visualization of color embeddings from different centers. Each dot represents an H&E slide image. Gray points represent all external data points that are not from UKHD or the highlighted center.




Extended Data Fig. 5 | Performance of Hetairos validated on EBRAINS DBTA data ($n = 3,110$ slides) and samples with low methylation scores (<0.8 , $n = 584$ slides) from the external centers. **a, Barplots showing the tumour subtype distribution of EBRAINS DBTA dataset, labelled according to the original class definitions of the dataset. **b**, Hetairos's predictive performance across different confidence intervals on EBRAINS DBTA data. The top row shows the distribution of prediction confidence, with high-confidence cases (50%) on the left and low-confidence cases (50%) on the right. Below, Sankey diagrams illustrate tumour classifications, approximately grouped and colour-coded by major tumour families despite different class definitions between EBRAINS**

DBTA and those predicted by Hetairos. The top-1 accuracy of high-confidence predictions and low confidence predictions are 85.6% and 50.2% respectively, calculated based on an expert evaluation of whether the predicted classes were consistent with the EBRAINS annotations. 190 samples in the low-confidence group were excluded from the accuracy calculation as their true classes were not included in Hetairos' label set. **c**, Hetairos top-1 and top-3 prediction concordance with the corresponding predictions from the methylation classifier. **d**, Hetairos's predictive performance across different confidence intervals compared to predictions from the methylation classifier.




Extended Data Fig. 6 | Hetairos report examples of Oligodendroglioma and astrocytoma. a, An example report of oligodendroglioma, IDH-mutant and 1p/19q-codeleted with high Hetairos's confidence and typical tumour patterns.

b, An example report of astrocytoma, IDH-mutant with a Hetairos's confidence of 0.47, and glioblastoma, IDH-wildtype with a confidence of 0.40. Typical tumour patterns are shown at the bottom of the figure.



Extended Data Fig. 7 | Hetairos report examples illustrating intra-tumour histological heterogeneity. a, An example report of astrocytoma, IDH-mutant. Blue: CNS infiltration zone; Green: spots of vascular proliferations, which are relevant criteria for assigning astrocytoma as grade 4 and therefore received higher scores in the heatmap for glioblastoma. Heatmaps of different predicted tumour classes are listed below in descending order of confidence. **b,** An example



report of spinal ependymoma. The heatmap clearly delineates the relevant areas of the spinal ependymoma. The dark blue areas show features resembling those of some pilocytic astrocytomas, which are correctly de-emphasized by Hetairos in this case. Heatmaps of different predicted tumour classes are listed below in descending order of confidence.




Extended Data Fig. 8 | Hetairos identifies heterogeneity within meningioma subtypes. **a**, Triplot showing the predicted probabilities for slides from three meningioma subtypes. **b**, Examples showcasing the predictive heatmaps generated by Hetairos for three meningioma cases, illustrating intra-tumour heterogeneity. Representative benign/intermediate patterns are shown below. **c**, Distribution of intra-slide prediction variability for the three meningioma

subtypes (meningioma benign: $n = 79$ slides; intermediate: $n = 35$ slides; malignant: $n = 5$ slides), showing that low heterogeneity only occurs in benign cases. Box plots show the median (centre line), 25th–75th percentile (box bounds), 5th–95th percentile (whiskers). **d**, Paired H&E and IHC samples were used to validate the intratumoral heterogeneity predicted by Hetairos. The highlighted regions in the heatmaps show high concordance with the Ki67-stained areas.

a



Extended Data Fig. 9 | Hetairos is robust to intratumoral heterogeneity. a, Example annotation of a slide to tumour/CNS (healthy) tissue. **b**, Hetairos top-1 prediction confidence across subsamples ($n = 50$ subsets within one slide) with varying fractions of tumour tissue. Box plots show the median (centre line), 25th–75th percentile (box bounds), 1.5× IQR (whiskers).



Extended Data Fig. 10 | Subsampling experiments. **a**, Scatter plot showing the correlation between training sample size and Hetairos's predicted overall accuracy. **b**, Scatter plot showing the correlation between training sample size and cross entropy values.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed
☐	☒ The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement
☒	☐ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☒	☐ The statistical test(s) used AND whether they are one- or two-sided <i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>
☒	☐ A description of all covariates tested
☒	☐ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐	☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☒	☐ For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
☒	☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☒	☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☒	☐ Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	No software/code was used to collect data.
Data analysis	Algorithms of this study were mostly programmed with Python (version 3.10.15) and libraries mainly involved were mainly OpenSlide (version 1.2.0), OpenCV (version 4.8.0), Timm (version 1.0.8), Pillow (9.5.0), NumPy (version 1.24.4), pandas (version 2.0.3), h5py (version 3.9.0) and Wandb (0.18.7). The preprocessing, feature extraction and training/test code of Hetairos can be accessed at https://github.com/gerstung-lab/Hetairos , along with the Jupyternotebook to reproduce the figures in the manuscript.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Restrictions apply to the availability of datasets used for training and internal validation, which were collected retrospectively under institutional and ethical approval and are therefore not publicly available. These datasets comprise routine clinical histopathology and DNA methylation data collected as part of standard diagnostic workup, and were not generated for research purposes; they are therefore not eligible for public redistribution. Requests for these datasets should be directed to the corresponding author at felix.sahm@med.uni-heidelberg.de. Requests will be reviewed within 4 weeks and evaluated according to institutional and departmental policies regarding patient privacy and intellectual property obligations. External validation datasets were obtained under data sharing agreements with the respective contributing institutes and cannot be redistributed. Access requests should be directed to the respective contributing institutes. Publicly available datasets used in this study included TCGA-LGG, TCGA-GBM and The Digital Brain Tumour Atlas (EBRAINS DBTA). Source data for Figures 1–8 and Extended Data Figures 1–10 have been provided as Source Data files. Additional data supporting the findings and reproducibility of this study are available at <https://github.com/gerstung-lab/Hetairos>.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\)](#), [and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender

Of the 5,905 samples used for training and internal validation, sex information was available for 4,967 samples (male:female=2,674:2,293), with 2,169:1,854 in the training set and 505:439 in the validation set. Of the 210 samples included in the Hetairos versus neuropathologist comparison, sex information was available for 176 samples (male: female = 97:79). Of the 857 samples included in UCL dataset, sex information was available for 543 samples (male:female=280:263) with 226:200 in the high-methylation-score subset and 63:54 in the low-methylation-score subset. For all other cohorts, samples were anonymised and corresponding sex information was not available. No exclusions were made based on race, ethnicity, sex, gender, or other social factors.

Reporting on race, ethnicity, or other socially relevant groupings

Participant selection was solely determined by the availability of histopathology images and matched diagnoses. No exclusions were made based on race, ethnicity, sex, gender, or other social factors. We did not independently collect, modify, or interpret these demographic variables.

Population characteristics

Participant selection was solely determined by the availability of histopathology images and matched diagnoses. No exclusions were made based on race, ethnicity, sex, gender, or other social factors.

Recruitment

Informed consent is waived for this study and no participant compensation was provided.

Ethics oversight

Ethics Committee of the Medical Faculty of the University of Heidelberg (S-649/2021). Slides from University College London were obtained under the BRAIN UK ethics approval (22/015).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

The study included 6115 slides (4961 tumours) from the UKHD dataset and 5498 slides (4645 tumours) from the external dataset. The number of datasets was determined by the availability of digitised H&E slides with matched methylation classifications from institutions.

Data exclusions

No data exclusions were performed.

Replication

The codes for replication including preprocessing and training/testing of Hetairos, are available at <https://github.com/gerstung-lab/Hetairos>.

Randomization

Samples were randomly assigned to 80% of the training and 20% of the validation for the UKHD dataset.

Blinding

Blinding was not applicable as this study mainly involved computational analysis of retrospective data without any experimental intervention

Blinding

or outcome assessment by human observers. For the prospective validation component, AI-based predictions were generated independently of and without access to clinical diagnostic workflows.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

Methods

- | n/a | Involved in the study |
|-------------------------------------|--|
| ☒ | ☐ Antibodies |
| ☒ | ☐ Eukaryotic cell lines |
| ☒ | ☐ Palaeontology and archaeology |
| ☒ | ☐ Animals and other organisms |
| ☒ | ☐ Clinical data |
| ☒ | ☐ Dual use research of concern |
| ☒ | ☐ Plants |

- | n/a | Involved in the study |
|-------------------------------------|---|
| ☒ | ☐ ChIP-seq |
| ☒ | ☐ Flow cytometry |
| ☒ | ☐ MRI-based neuroimaging |

Plants

Seed stocks

Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.

Novel plant genotypes

Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.

Authentication

Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosaicism, off-target gene editing) were examined.